Insulet (NASDAQ:PODD) Stock Price Target Raised at Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised its Insulet price target to $180 from $160 and maintained an Outperform rating, implying about 16.45% upside from the previous close.
• Insulet beat quarterly expectations, reporting EPS of $1.99 versus $1.59 expected and revenue of $842 million versus $832.6 million expected; revenue grew 19.2% year over year.
• Shares fell 6.3% in Thursday trading, while analyst views remain mixed: the consensus rating is Hold, and concerns include slower expected growth in 2027 and competition for Omnipod.

Insulet (NASDAQ:PODD - Get Free Report) had its price target upped by investment analysts at Royal Bank Of Canada from $160.00 to $180.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an "outperform" rating on the medical instruments supplier's stock. Royal Bank Of Canada's target price would suggest a potential upside of 16.45% from the stock's previous close.

PODD has been the topic of a number of other research reports. Sanford C. Bernstein lifted their target price on Insulet from $175.00 to $200.00 and gave the company an "outperform" rating in a research report on Thursday. TD Cowen reissued a "hold" rating on shares of Insulet in a research report on Wednesday. Oppenheimer cut shares of Insulet from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Wall Street Zen cut shares of Insulet from a "buy" rating to a "hold" rating in a research report on Saturday, October 24th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $200.00 price target on shares of Insulet in a research report on Wednesday. Thirteen investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Insulet presently has a consensus rating of "Hold" and an average price target of $190.00.

Insulet Trading Down 6.3%

Shares of PODD traded down $10.45 during mid-day trading on Thursday, reaching $154.57. The stock had a trading volume of 738,488 shares, compared to its average volume of 1,394,949. Insulet has a 52-week low of $126.40 and a 52-week high of $354.88. The firm has a market cap of $10.72 billion, a price-to-earnings ratio of 28.86, a P/E/G ratio of 1.22 and a beta of 1.06. The business's fifty day moving average is $141.65 and its 200 day moving average is $178.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.59 by $0.40. The business had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business's revenue was up 19.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.24 EPS. On average, sell-side analysts predict that Insulet will post 6.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Insulet

Institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new position in shares of Insulet during the 2nd quarter worth approximately $1,018,582,000. Arrowstreet Capital Limited Partnership increased its position in Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock worth $258,088,000 after buying an additional 1,011,369 shares in the last quarter. Man Group plc purchased a new position in Insulet during the second quarter worth $78,746,000. Bank of America Corp DE acquired a new position in shares of Insulet in the second quarter worth $64,921,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Insulet in the second quarter worth $60,615,000.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99 versus $1.59 expected and revenue of $842 million versus $832.6 million expected. Revenue grew 19.2% year over year, and reports noted margin expansion and a stronger 2026 outlook, though the full-year EPS outlook was maintained. Insulet Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company announced a $1 billion share repurchase program, which may support per-share value and signal confidence in its business outlook. Insulet Announces $1 Billion Equity Buyback
• Positive Sentiment: Several firms raised their price targets: Bernstein to $200 with an Outperform rating, RBC to $180 with Outperform, and Wells Fargo to $172. RBC Raises Insulet Price Target
• Neutral Sentiment: UBS also lifted its target, to $171 from $150, but kept a Neutral rating—recognizing improved prospects without signaling a stronger recommendation. UBS Adjusts Insulet Price Target
• Negative Sentiment: Management expects slower growth in 2027 and anticipates rivals taking some share from its Omnipod product. Those concerns may temper enthusiasm after the earnings beat and help explain why the stock is lower in Thursday trading. CEO Sees Slower Growth and Competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.